We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

40 hedge funds and large institutions have $128M invested in Eiger BioPharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

75% more capital invested

Capital invested by funds: $73.1M → $128M (+$54.7M)

18% more funds holding

Funds holding: 34 → 40 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

Holders
40
Holders Change
+6
Holders Change %
+17.65%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
9
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
+$20.2M
2
EAM
Eagle Asset Management
Florida
+$5.3M
3
SFM
Sphera Funds Management
Israel
+$1.67M
4
Axa
Axa
France
+$535K
5
RPAM
Rhenman & Partners Asset Management
Sweden
+$510K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$4.55M
2
BFA
BlackRock Fund Advisors
California
-$1.71M
3
FCM
Farallon Capital Management
California
-$801K
4
BIT
BlackRock Institutional Trust
California
-$630K
5
State Street
State Street
Massachusetts
-$480K
Name Holding Trade Value Shares
Change 		Change in
Stake
BPC
26
Banque Pictet & Cie
Switzerland
$244K +$25K +5 +17%
BIM
27
Baldwin Investment Management
Pennsylvania
$234K – – –
V
28
Veritable
Delaware
$234K – – –
Goldman Sachs
29
Goldman Sachs
New York
$219K -$225K -45 -60%
LP
30
LMR Partners
United Kingdom
$219K +$150K +30 New
TC
31
TFS Capital
Pennsylvania
$216K +$150K +30 New
Millennium Management
32
Millennium Management
New York
$195K +$135K +27 New
CS
33
Credit Suisse
Switzerland
$180K +$125K +25 New
Deutsche Bank
34
Deutsche Bank
Germany
$148K +$85.1K +17 +425%
Barclays
35
Barclays
United Kingdom
$121K +$85.1K +17 New
BA
36
BlackRock Advisors
Delaware
$85K +$50K +10 +500%
Morgan Stanley
37
Morgan Stanley
New York
$38K -$250K -50 -91%
BIM
38
BlackRock Investment Management
Delaware
$16K -$150K -30 -94%
Wells Fargo
39
Wells Fargo
California
$16K +$10K +2 New
TRCT
40
Tower Research Capital (TRC)
New York
$8K -$25K -5 -83%
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$3K – – –
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$2K – – –
State Street
43
State Street
Massachusetts
– -$480K -89 Closed
SCA
44
SAC Capital Advisors
Connecticut
– -$415K -77 Closed
NFA
45
Nationwide Fund Advisors
Ohio
– -$372K -69 Closed
TCIM
46
TIAA CREF Investment Management
New York
– -$256K -48 Closed
TA
47
Teachers Advisors
New York
– -$182K -34 Closed
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
– -$137K -26 Closed
Citigroup
49
Citigroup
New York
– -$2K – –
U
50
UBS
Switzerland
– -$1K – –
1
2

EIGR Hedge Fund Activity: Q2 2014 in Review

40 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2014, worth a combined $128M — up 75% from $73.1M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new EIGR positions and 6 closed out — a net gain of 6 holders — while 9 added to existing stakes and 12 trimmed.

The largest buyer was HighTower Advisors, adding an estimated $20.2M. The largest seller was JP Morgan Chase, cutting an estimated $4.55M.

  • 40 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2014, up from 34 in Q1 2014.
  • Funds reported $128M of Eiger BioPharmaceuticals, Inc. stock for Q2 2014, up 75% quarter-over-quarter.
  • 12 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2014 and 6 closed out, a net change of +6 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2014 was HighTower Advisors, an estimated $20.2M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2014 was JP Morgan Chase, an estimated $4.55M sold.

Based on aggregated 13F filings for Q2 2014.